Pharmplanet introduced the original German hepatoprotector Prohepar to the market of Ukraine

 
 
Progepar_30_09_2013
Progepar_30_09_2013
 
Spread the Word
Listed Under

Tags:
* Pharmplanet
* Distributor
* Prohepar
* Hepatoprotector

Industry:
* Medical

Location:
* Kyiv - Kyiv - Ukraine

Subject:
* Products

KYIV, Ukraine - Dec. 4, 2014 - PRLog -- The product portfolio of the company Pharmplanet has been expanded to a new drug Prohepar - synergistic hepatoprotective combinationbased on liver hydrolysate received from calves and enriched by cyanocobalamin, choline, myo-inositol and cysteine.

Pharmaceuticals company Nordmark Arzneimittel GmbH - Germany's leading developer and manufacturer of medical products produces this drug. The company is GMP (EU) and FDA (USA) certified which is an international guarantee of quality and safety of the drug.

A unique feature of Prohepar is due to its combined composition comprising the extract of calf liver obtained by a special technique as well as vitamins (B4, B8) and amino acids which guarantees a high therapeutic efficiency of the drug.

Natural extract of calves’ liver promotes rapid normalization of antitoxic and protein synthetic functions of liver and activation of regenerative processes even while its severe damage. Choline and myo-inositol regulate the level of glycogen and lipids in the liver, cysteine - a powerful antioxidant - protects hepatic cells against toxic agents (free radicals, alcohols and others). It should be noted that Prohepar is also a source of easily assimilated “organic” chrome that allows covering more than 50% of the daily requirement for this trace mineral.

Experimental researches in European countries indicate its undoubted hepatoprotective effect of the drug in the treatment of chronic liver disease of various origins. Prohepar can be taken also by healthy people in violation of the daily diet, excessive alcohol or drug load on the liver.

Long history of successful use of Prohepar in Europe and Japan, as well as an increase in the number of patients with liver disease and metabolic syndrome with type-2 diabetes, obesity and fatty liver disease - all this confirms the relevance and demand trends of novelty in the pharmaceutical market of Ukraine.

A contract between the German manufacturer and the company Pharmplanet on the official distribution of the drug was signed in August 2014. In November, Prohepar has already appeared in Ukrainian pharmacy chains.

Contact
Pharmplanet
***@pharmplanet.com.ua
End
Source:
Email:***@pharmplanet.com.ua Email Verified
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Pharmplanet News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share